Matches in Wikidata for { <http://www.wikidata.org/entity/Q86289661> ?p ?o ?g. }
Showing items 1 to 32 of
32
with 100 items per page.
- Q86289661 description "clinical trial" @default.
- Q86289661 description "ensayu clínicu" @default.
- Q86289661 description "klinisch onderzoek" @default.
- Q86289661 description "клінічне випробування" @default.
- Q86289661 description "կլինիկական փորձարկում" @default.
- Q86289661 name "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]" @default.
- Q86289661 name "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]" @default.
- Q86289661 type Item @default.
- Q86289661 label "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]" @default.
- Q86289661 label "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]" @default.
- Q86289661 prefLabel "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]" @default.
- Q86289661 prefLabel "A Study to Understand Effectiveness and Safety of ABP 938 Compared to Aflibercept (Eylea®) in Patients Suffering With Neovascular Age-related Macular Degeneration [Neovascular (Wet) AMD]" @default.
- Q86289661 P1050 Q86289661-77C225EF-D081-4996-9A43-FC988607B4BD @default.
- Q86289661 P1132 Q86289661-CF6A970E-99DF-4D01-A8BB-BF3F2B2C87F9 @default.
- Q86289661 P1476 Q86289661-F4E21341-9962-4822-B8D2-4D3503FADE5C @default.
- Q86289661 P2899 Q86289661-76263FEF-7D77-410C-9C8C-79A40E72EF63 @default.
- Q86289661 P3098 Q86289661-7E7BD7F8-8F4A-4499-826A-14225F39DFCD @default.
- Q86289661 P31 Q86289661-0B5C6AEC-C9FD-44DB-9B61-E5EA31661B38 @default.
- Q86289661 P580 Q86289661-146B5DAA-7C8C-4DF7-8B7B-F83D82250959 @default.
- Q86289661 P582 Q86289661-0600E1C9-483B-4809-B865-9792DF2A5983 @default.
- Q86289661 P6099 Q86289661-CE82F365-0A8D-4797-9838-C4DC904AEEF6 @default.
- Q86289661 P8363 Q86289661-E474E243-8BF2-4879-BE95-3EF42CE6D097 @default.
- Q86289661 P1050 Q27429789 @default.
- Q86289661 P1132 "+566" @default.
- Q86289661 P1476 "A Randomized, Double-masked, Phase 3 Study of ABP 938 Efficacy and Safety Compared to Aflibercept (Eylea®) in Subjects With Neovascular Age-related Macular Degeneration" @default.
- Q86289661 P2899 "+50" @default.
- Q86289661 P3098 "NCT04270747" @default.
- Q86289661 P31 Q30612 @default.
- Q86289661 P580 "2020-03-31T00:00:00Z" @default.
- Q86289661 P582 "2021-05-31T00:00:00Z" @default.
- Q86289661 P6099 Q42824827 @default.
- Q86289661 P8363 Q78089383 @default.